Overview
Zinc Thymulin is a metallopeptide consisting of the nonapeptide thymulin (pyrGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) complexed with a single zinc ion, which is required for its biological activity. Thymulin is naturally secreted by thymic epithelial cells and plays a central role in T-cell differentiation and immune regulation. In hair research, Zinc Thymulin has been studied as a topical intervention for androgenetic alopecia, with evidence suggesting it extends the anagen (growth) phase of the hair cycle and delays follicular miniaturization.
Mechanism of action
Thymulin binds zinc in an equimolar ratio through coordination with serine and asparagine residues, forming the biologically active metallopeptide. In the immune system, Zinc Thymulin induces T-cell differentiation markers and enhances CD4+ and CD8+ subset function via thymulin receptors on lymphoid precursors. In hair follicle biology, Zinc Thymulin promotes anagen phase extension by stimulating keratinocyte proliferation and reducing local inflammatory cytokines (IL-1β, TNF-α) implicated in follicular miniaturization. It may also activate dormant hair follicle stem cells, promoting follicle neogenesis and increasing hair follicle density. Zinc's role is dual: activating the peptide's receptor-binding conformation and providing anti-inflammatory and 5α-reductase-modulating activity locally.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| androgenetic alopecia (topical research use) | topical | 0.01–0.05 % | once or twice daily | Used in pilot trials at 0.01–0.05% in topical solution applied to the scalp. Systemic nasal routes have also been explored in research settings. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
A pilot randomized controlled trial published in the Journal of Drugs in Dermatology analyzed topical Zinc Thymulin in patients with androgenetic alopecia, reporting significant increases in anagen hair count and decreases in telogen count versus placebo after 6 months. A published safety and efficacy analysis in a peer-reviewed journal confirmed tolerability with no systemic absorption detected. Most studies are manufacturer-sponsored and small in scale. No large Phase II/III trials in hair loss have been published as of 2026.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Zinc Thymulin for synergistic effects.
Legal status
Available as a research peptide and from some compounding pharmacies for topical use. Not FDA-approved for any indication. Some practitioners prescribe compounded formulations off-label for hair loss.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.